← All Werewolf Therapeutics, INC filings

Werewolf Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
HOWL
Werewolf Therapeutics, INC
10-K: Werewolf Therapeutics Faces Going Concern Doubt Amid Restructuring
Werewolf Therapeutics, Inc. announced a significant restructuring, including a 64% workforce reduction, and is exploring strategic alternatives to address substantial doubt about its ability to continue as a going concern.
NASDAQ
HOWL
Werewolf Therapeutics, INC
10-K: Werewolf Therapeutics Reports 2024 Financial Results and Provides Business Update
Werewolf Therapeutics details its 2024 financial performance and outlines key developments in its clinical programs.
NASDAQ
HOWL
Werewolf Therapeutics, INC
10-K: Werewolf Therapeutics Reports 2023 Financial Results and Provides Clinical Pipeline Update
Werewolf Therapeutics reports a net loss of $37.4 million for 2023, alongside progress in clinical trials for its lead product candidates and a collaboration with Jazz Pharmaceuticals.